The FMDV L protease targets LGP2 helicase, which ultimately results in lower levels of IFN-β and antiviral activity (41). Furthermore, the downregulation of IKK/NF-κB has been observed in human lung cancer cells that express recombinant FMDV VP1 (42). This evidence concerns the gene DHX58 and lung carcinoma.